<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Purulent pericarditis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Purulent pericarditis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Purulent pericarditis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Massimo Imazio, MD, FESC, FHFA</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin M LeWinter, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prior to the widespread use of antibiotics, purulent pericarditis was a frequent complication of pneumococcal pneumonia. In modern times, most cases of purulent pericarditis are associated with nosocomial bloodstream infections (such as in the setting of dialysis), thoracic surgery, or immunosuppression (eg, HIV, chemotherapy).</p><p>Galen (AD 129 to 217) was one of the first clinicians to recognize and attempt to treat purulent pericarditis. While removing the "putrefied" sternum of a patient with posttraumatic pericarditis, he directly observed "mortification of the pericardium" in a patient who survived [<a href="#rid1">1</a>]. </p><p>By the beginning of the 19th century, clinicians were aware that purulent fluid collections in the pericardium could occur in patients with pneumonia and pleurisy, and were attempting treatment with percutaneous drainage and pericardiectomy [<a href="#rid2">2</a>].</p><p>Issues related to purulent pericarditis will be reviewed here. Other causes of pericarditis and the management of acute pericarditis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">"Etiology of pericardial disease"</a> and  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/15800.html" rel="external">"Acute pericarditis: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Purulent pericarditis is defined as a localized infection of the pericardial space characterized by gross pus in the pericardium or microscopic purulence (&gt;20 leukocytes per oil immersion field). This distinction is important since purulent material in the pericardium is not synonymous with infectious pericarditis, and not all infections produce purulent effusions. As an example, pericarditis due to Mycoplasma hominis or viral infection is rarely macroscopically or microscopically purulent. By contrast, a variety of noninfectious conditions produce an inflammatory exudate that may contain &gt;50,000 white cells/microL [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence and etiologies of purulent pericarditis have changed significantly in the antibiotic era. In modern practice, purulent pericarditis is relatively uncommon. In a retrospective review performed in Spain between 1972 and 1991, only 33 cases were observed among an inpatient population of 593,600; the diagnosis was not established until postmortem in 14 of these cases [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">Predisposing factors</span><span class="headingEndMark"> — </span>One study compared 55 patients who died from purulent pericarditis during the post antibiotic era with 145 patients who died from the same condition during the period 1889 to 1943 [<a href="#rid5">5</a>]. The following conclusions were reached:</p><p class="bulletIndent1"><span class="glyph">●</span>In the preantibiotic period, the majority of patients had a primary infectious disease such as pneumonia (72/145), endocarditis (11/145), or other (41/145). Other infectious foci resulting in bacteremia and pericardial infection included the central nervous system, bone, pelvic, skin, and otic structures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the modern era, only 22 percent of patients with purulent pericarditis had a recognized underlying primary infectious disease, such as pneumonia (3/55) or meningitis (4/55).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the preantibiotic era, only 14 percent of patients had an underlying non-infectious condition or disease. By contrast, in modern practice, 78 percent had one or more predisposing causes including recent thoracic surgery (12/55), chronic renal failure (9/55), or malignancy (8/55).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the antibiotic era, many patients with purulent pericarditis also had preexisting pericardial diseases due to conditions or causes, such as uremia, tumor, or collagen vascular disease.</p><p></p><p>Other predisposing factors include immunosuppression, alcohol abuse, thoracic surgery, and chest trauma [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H5"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>There are several mechanisms by which patients develop purulent pericarditis:</p><p class="bulletIndent1"><span class="glyph">●</span>Direct spread from an intrathoracic focus of infection, including extension from a myocardial focus or direct contamination from trauma or thoracic surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Hematogenous spread</p><p class="bulletIndent1"><span class="glyph">●</span>Extension from a subdiaphragmatic suppurative focus</p><p></p><p>In the preantibiotic era, direct pulmonary extension accounted for the probable route of acquisition in almost two-thirds of cases. In two of the larger series of cases of purulent pericarditis in the antibiotic era, direct pulmonary extension accounted for 20 and 25 percent of infections respectively, while hematogenous spread occurred in 29 and 22 percent, perforating injury or surgery in 24 and 29 percent, and myocardial abscess and/or endocarditis in 22 and 14 percent [<a href="#rid1">1,5</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Direct spread of infection from an intrathoracic focus</span><span class="headingEndMark"> — </span>Virtually any organism can spread from infected lung into the pericardium; Streptococcus pneumoniae is the most common organism. In a review of 113 cases of pneumococcal pericarditis between 1900 and 1973, 93 percent of cases had a preceding pneumonia and 67 percent had pneumonia with empyema [<a href="#rid7">7</a>].</p><p>Infection can also spread to the pericardium following esophageal perforation. This complication is usually devastating, with a survival rate of only 17 percent in one review of 60 patients with pyopneumopericardium secondary to esophageal perforation [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Hematogenous spread</span><span class="headingEndMark"> — </span>Virtually any organism can spread to the pericardial sac via the hematogenous route. Numerous case reports document an array of common and uncommon bacteria and fungi that have caused purulent pericarditis. Of these pathogens, Staphylococcus aureus and various streptococci are most common [<a href="#rid2">2</a>].</p><p>Pneumonia or empyema may be accompanied by bacteremia; in such cases, patients can develop pericardial infection from hematogenous spread or via microscopic septic emboli into the bronchial arterial circulation, with secondary spread to the pericardium, myocardium, or adjacent mediastinum [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Extension from a myocardial focus</span><span class="headingEndMark"> — </span>Infective endocarditis can be complicated by perivalvular ring abscess, septic coronary artery emboli, or myocardial abscess, all of which can result in direct extension of infection to the pericardium. In addition, occasionally a sterile inflammatory pericardial collection can develop in the setting of endocarditis. Therefore a clinical presentation of pericarditis and/or pericardial fluid in the setting of endocarditis or mural thrombus does not always imply purulent pericarditis, although such findings should be evaluated carefully.</p><p>Rarely, myocardial infarction can be complicated by infection, resulting in abscess formation and secondary purulent pericarditis [<a href="#rid9">9</a>]. A myocardial abscess can also occur as metastatic infection in patients with bacteremia due to organisms such as S. aureus or Salmonella. Such patients may, in turn, develop purulent pericarditis from direct extension of the abscess into the pericardium. In rare cases, coronary artery stents can become infected with S. aureus, resulting in coronary artery aneurysms and purulent pericarditis [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Perforating injury or surgery</span><span class="headingEndMark"> — </span>Purulent pericarditis may develop as an early or late complication of perforating injury or thoracic surgery. Most of these patients have associated clinical signs or symptoms of mediastinitis or empyema. In some post-thoracotomy patients it may be difficult to distinguish between pericardial injury syndrome and purulent pericarditis. S. aureus, enteric gram-negative rods, and Candida species are the most likely pathogens, although virtually any bacteria can cause purulent pericarditis in such situations. Purulent pericarditis due to knife wounds is often polymicrobial; bullet or shell fragment wounds may result in clostridial pericarditis [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/4937.html" rel="external">"Pericardial complications of myocardial infarction"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Extension of infection from a subdiaphragmatic suppurative focus</span><span class="headingEndMark"> — </span>Undrained subphrenic abscesses result in pericardial extension in 2 percent of cases [<a href="#rid11">11</a>]. Rare subdiaphragmatic processes that can result in purulent pericarditis include intrahepatic amoebic abscess, ruptured duodenal or gastric ulcer, infected choledochal cyst, peritonitis, or erosion of intraabdominal tumor into the pericardium [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H11"><span class="h1">MICROBIOLOGY</span><span class="headingEndMark"> — </span>S. aureus is the most common cause of purulent pericarditis, accounting for 31 percent of cases in one series and 22 percent in another [<a href="#rid1">1,5</a>]. In these reviews, gram-positive organisms caused approximately 40 to 45 percent of all infections; polymicrobial infections were uncommon. S. pneumoniae is the most common cause of purulent pericarditis in the setting of direct spread of infection from an intrathoracic focus. Salmonella bacteremia can also result in purulent pericarditis [<a href="#rid14">14</a>]. Many other bacterial organisms have been reported to cause purulent pericarditis, including rare cases of infection with anaerobic bacteria [<a href="#rid15">15</a>].</p><p>Fungal pathogens have become more common causes of purulent pericarditis. In one series of 26 patients, fungi were the etiology of purulent pericarditis in 19 percent of cases; these patients had predisposing factors for candidemia [<a href="#rid1">1</a>]. In two reviews summarizing the clinical features of 10 cases of Candida pericarditis, six patients had one or more well known predisposing factors for candidemia including parenteral hyperalimentation, steroid administration, prolonged antibiotic therapy, malignancy, burns, or alcoholism [<a href="#rid16">16,17</a>]. The remaining four patients had had recent cardiac surgery.</p><p>Tuberculosis is the most common cause of subacute or chronic purulent pericarditis in resource-limited countries, particularly where the prevalence of HIV is high [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/8002.html" rel="external">"Tuberculous pericarditis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Purulent pericarditis is typically an acute illness characterized by high fever, tachycardia, cough, and chest pain (regardless of the pathogen involved or the pathogenesis of infection) [<a href="#rid6">6</a>]. In one series, the mean duration of symptoms before hospitalization was three days (range one to six days) [<a href="#rid1">1</a>]. In another series, clinical features of pericarditis developed a mean of 10 days after onset of predisposing infection [<a href="#rid4">4</a>].</p><p>Fever is present in virtually all patients [<a href="#rid1">1,4</a>]. Chest pain is less common in purulent pericarditis than in acute pericarditis of other etiologies (25 to 37 percent of patients) [<a href="#rid1">1,4</a>]. Chest pain may be pleuritic or nonpleuritic. In the postoperative setting, most patients with purulent pericarditis have other signs of mediastinitis or sternal wound infection [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/7014.html" rel="external">"Postoperative mediastinitis after cardiac surgery"</a> and  <a class="medical medical_review" href="/z/d/html/4957.html" rel="external">"Etiology of pericardial disease"</a>.) </p><p>A pericardial friction rub is present in 35 to 45 percent of patients with purulent pericarditis [<a href="#rid1">1,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Pericardial friction rub'</a>.)</p><p>The incidence of cardiac tamponade has varied from 42 to 77 percent in different series; sudden cardiac decompensation can rapidly lead to death [<a href="#rid1">1,4</a>]. There is indirect evidence that the concomitant use of antiplatelet and antithrombotic therapies is not associated with an increased risk of cardiac tamponade; however, these data were obtained in patients with idiopathic or viral acute pericarditis, so the application to patients with purulent pericarditis is uncertain [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p>The majority of patients with purulent pericarditis are acutely ill; occasional patients have a relatively indolent course of infection. One such case was reported in a hemodialysis patient who was treated twice for lengthy periods for S. aureus bacteremia and then presented with dyspnea, fatigue, and chest discomfort [<a href="#rid20">20</a>]. Chest computed tomography (CT) revealed a large anterior mediastinal mass compressing the heart  (<a class="graphic graphic_diagnosticimage graphicRef70734" href="/z/d/graphic/70734.html" rel="external">image 1</a>); the patient underwent pericardiectomy and drainage of pus from the pericardial space. Salmonella may also cause a more indolent course of purulent pericarditis.</p><p class="headingAnchor" id="H13"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>General laboratory tests are nonspecific in purulent pericarditis. Anemia and leukocytosis are present in most patients, although those receiving chemotherapy may be leukopenic.</p><p>In one case series, chest radiographs were abnormal in 25 of 26 patients with purulent pericarditis  (<a class="graphic graphic_diagnosticimage graphicRef57640" href="/z/d/graphic/57640.html" rel="external">image 2</a>) [<a href="#rid1">1</a>]. The findings included:</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiomegaly (19/25)</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary infiltrates (12/25)</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural effusions (8/25)</p><p class="bulletIndent1"><span class="glyph">●</span>Mediastinal widening (3/25)</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Electrocardiography</span><span class="headingEndMark"> — </span>The majority of patients with purulent pericarditis have electrocardiographic findings typical of acute pericarditis. However, the electrocardiogram may be normal in 10 to 35 percent of patients [<a href="#rid1">1,4</a>]. (See  <a class="medical medical_review" href="/z/d/html/4940.html" rel="external">"Acute pericarditis: Clinical presentation and diagnosis", section on 'Electrocardiogram'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Echocardiography</span><span class="headingEndMark"> — </span>Echocardiography is very useful for detecting fluid in patients with purulent pericarditis, but cannot distinguish between purulent collections and sterile inflammatory effusions. (See  <a class="medical medical_review" href="/z/d/html/5299.html" rel="external">"Echocardiographic evaluation of the pericardium"</a> and  <a class="medical medical_review" href="/z/d/html/4941.html" rel="external">"Pericardial effusion: Approach to diagnosis", section on 'Cardiac imaging'</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of purulent pericarditis can be overlooked and delayed, particularly since it can be a complication of a variety of primary infectious diseases, trauma, surgery, and diseases in adjacent structures [<a href="#rid5">5</a>]. The widespread availability of two-dimensional echocardiography and computerized tomography has improved the antemortem diagnosis. Ultimately, however, the diagnosis of purulent pericarditis is established by obtaining pericardial fluid for culture and microscopy. Since many patients with purulent pericarditis have clinical signs compatible with tamponade, this procedure can be both diagnostic and therapeutic.</p><p>The diagnosis of purulent pericarditis can be especially difficult when patients with preexisting conditions associated with pericardial effusions develop fever and leukocytosis. In addition, some pathogens (such as Neisseria meningitidis) cause sterile pericardial inflammatory fluid during the convalescent stage of illness, presumably immune-mediated [<a href="#rid21">21,22</a>]. Distinguishing sterile inflammation from purulent pericarditis is difficult.</p><p class="headingAnchor" id="H17"><span class="h2">Pericardiocentesis</span><span class="headingEndMark"> — </span>The diagnosis of purulent pericarditis is established by obtaining pericardial fluid for culture and microscopy [<a href="#rid6">6</a>]. Echocardiographically-guided pericardiocentesis using portable echocardiographic equipment is preferable [<a href="#rid23">23</a>]. Alternatively, pericardiocentesis can be performed by a "blind" subxiphoid approach or under fluoroscopic guidance and electrocardiographic needle monitoring. (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management", section on 'Technique'</a>.)</p><p>Pericardial fluid should be sent for protein, glucose and cell count, along with Gram stain, acid fast stain, fungal stain, and cultures. Typically the protein concentration is high and glucose levels are less than 35 mg/dL (2 mmol/L). Pericardial fluid leukocyte counts generally are markedly elevated, ranging from 6000 to 240,000/microL. It is important to obtain an adequate sample of pericardial fluid for culture; swabs taken at the time of surgery are not adequate for obtaining cultures. A minimum of 0.5 mL of fluid should be sent to the microbiology laboratory but a sample of 1 mL or greater is preferred.</p><p class="headingAnchor" id="H28697014"><span class="h2">Additional investigations</span><span class="headingEndMark"> — </span>For circumstances in which purulent pericarditis is accompanied by bacterial pneumonia, urinary S. pneumoniae antigen testing may be a useful diagnostic tool [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H18"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Treatment for purulent pericarditis consists of pericardial drainage and antimicrobial therapy [<a href="#rid6">6</a>]. The best method of drainage remains controversial. Since purulent pericarditis is often a rapidly progressive and fatal infection, the expertise and experience of local clinicians and the availability of technology usually determines which of the following techniques is utilized. (See  <a class="medical medical_review" href="/z/d/html/143123.html" rel="external">"Pericardial effusion: Approach to management", section on 'Choice of pericardial drainage procedure'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Pericardial drainage</span><span class="headingEndMark"> — </span>A number of options are available for drainage of the infected pericardial fluid.</p><p class="bulletIndent1"><span class="glyph">●</span>Pericardiocentesis – Pericardiocentesis is the simplest and often the fastest way to drain the pericardial space. However, thick fluid may either drain poorly or result in loculations in the pericardial space. Furthermore, pericardial constriction may occur following recovery if pericardiocentesis is the primary drainage method [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1">Fibrin formation appears to be an essential step in the evolution to constrictive pericarditis and persistent purulent pericarditis. Because of potential morbidity associated with pericardiectomy, intrapericardial fibrinolysis during pericardiocentesis may be considered as a less invasive effort to prevent persistent purulent pericarditis and constrictive pericarditis [<a href="#rid25">25,26</a>]. Nevertheless, if pericardiocentesis is not feasible or if fibrinolysis fails, pericardiectomy remains the primary option for complete eradication of infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subxiphoid pericardiotomy – Subxiphoid pericardiotomy usually allows more complete and permanent drainage than pericardiocentesis because a pericardial "window" is established during the procedure and because manual lysis of adhesions and loculations is easily accomplished with the finger of the operating surgeon. This procedure is usually performed in an operating room, but, when necessary, can be performed at the bedside using local anesthesia [<a href="#rid27">27</a>]. This approach was recommended as the preferable course of management by the 2015 ESC guidelines [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Postoperative constrictive pericarditis can occur following this procedure, but is uncommon. A detailed discussion of constrictive pericarditis is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4938.html" rel="external">"Constrictive pericarditis: Diagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pericardiectomy – Pericardiectomy has a higher morbidity and mortality than subxiphoid pericardiotomy. However, pericardiectomy usually achieves complete drainage, and is frequently required in patients with dense adhesions, loculated and thick purulent effusion, recurrent tamponade, persistent infection, and progression to constriction. A full discussion of pericardiectomy is presented separately. (See  <a class="medical medical_review" href="/z/d/html/140886.html" rel="external">"Constrictive pericarditis: Management and prognosis", section on 'Treatment of late (chronic) disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Video-assisted thoracic surgery – Video-assisted thoracic surgery (VATS) requires intubation and deflation of the left lung. It is usually performed through a small left chest incision. A pericardial window can usually be performed with this procedure, but complete pericardial stripping is not possible. Although this procedure usually achieves good drainage of the pericardial space, it adds little to a subxiphoid pericardiotomy and carries more risk. </p><p></p><p>Intrapericardial fibrinolysis has been proposed as a less invasive method than pericardiectomy for prevention of persistent purulent pericarditis and constrictive pericarditis, and early consideration of this approach is warranted to prevent both constrictive and persistent purulent pericarditis; however, pericardiectomy remains the preferred approach for complete eradication of infection. </p><p>Experimental data demonstrate that fibrin formation, which occurs during the first week of the disease, is an essential step in the evolution to constrictive pericarditis and persistent purulent pericarditis. In a clinical review including 40 patients who underwent intrapericardial fibrinolysis for management of purulent pericarditis, only two (treated by late fibrinolysis) encountered failure requiring pericardiectomy [<a href="#rid25">25</a>]. No patient encountered clinical or echocardiographic features of constriction during follow-up, and only one serious complication was described. </p><p class="headingAnchor" id="H20"><span class="h2">Antimicrobial therapy</span><span class="headingEndMark"> — </span>Intravenous antimicrobial therapy should be started as soon as the diagnosis of purulent pericarditis is suspected. Initial empiric antibiotic treatment should include coverage for the likely or suspected pathogens [<a href="#rid6">6</a>]. (See <a class="local">'Microbiology'</a> above.)</p><p class="headingAnchor" id="H21"><span class="h3">Empiric regimen</span><span class="headingEndMark"> — </span>The selection of an empiric regimen depends on careful consideration of patient-specific factors that can give clues to an etiologic diagnosis. These factors include:</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the patient is immunosuppressed</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the infection began in a health-care setting or in the community</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a concurrent infection at another body site</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of intravascular lines or prosthetic devices</p><p class="bulletIndent1"><span class="glyph">●</span>Local patterns of antimicrobial resistance</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the patient has received recent antimicrobial therapy</p><p></p><p>In general, empiric therapy for infections that occur in immunosuppressed patients or in a health care setting should include coverage for both gram-positive and gram-negative bacterial pathogens. Possible regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> (15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose); goal is a vancomycin trough serum level of 15 mcg/mL or greater, plus either </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">Ceftriaxone</a> (2 g IV once daily), <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> (2 g every eight hours) or <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> (3 mg/kg per 24 hours divided equally in two or three doses) <strong>OR</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A carbapenem, such as <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> (500 mg IV every six hours) or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (1 g IV every eight hours) <strong>OR</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A beta-lactam plus beta-lactamase inhibitor, such as ticarcillin-clavulanate (3.1 g IV every four hours), <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (4.5 g every six hours) <strong>or</strong> <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> (3 g IV every six hours) <strong>OR</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">Cefepime</a> (2 g IV every 12 hours)</p><p></p><p>In addition, empiric therapy with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (200 to 400 mg intravenously once daily) is recommended for patients who are severely immunosuppressed, for those who have had recent care in an intensive care unit, or for recipients of recent broad-spectrum antimicrobial therapy.</p><p class="headingAnchor" id="H22"><span class="h3">Pathogen-directed therapy</span><span class="headingEndMark"> — </span>After a microbiologic diagnosis has been established by blood and/or pericardial fluid cultures, therapy should be directed at the specific pathogen isolated. If a methicillin-susceptible S. aureus is recovered from cultures of the blood and/or pericardial fluid, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> or <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> (2 g IV every four hours) should be substituted for <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> in patients who are not allergic to beta-lactam antibiotics. There is no role for pericardial instillation of antibiotic, since therapeutic levels in the pericardial fluid are achieved by intravenous administration of antibiotics.</p><p class="headingAnchor" id="H23"><span class="h3">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of therapy must be individualized. Intravenous therapy should be continued until fever and clinical signs of infection have resolved and until the white blood cell count is normal. In general this usually consists of a total of approximately two to four weeks of therapy, depending on the adequacy of drainage and the antimicrobial susceptibility of the infecting bacteria. </p><p class="headingAnchor" id="H3443867150"><span class="h3">Prognosis</span><span class="headingEndMark"> — </span>Purulent pericarditis is a life-threatening disease. Reported mortality rates are between 20 and 30 percent. Constrictive pericarditis occurs over the course of purulent pericarditis in at least 3.5 percent of cases and is possible in up to 20 to 30 percent [<a href="#rid25">25,28</a>]. Timely recognition and treatment is of paramount importance for better outcomes and to prevent the development of constriction.</p><p class="headingAnchor" id="H1826633009"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116655.html" rel="external">"Society guideline links: Pericardial disease"</a>.)</p><p class="headingAnchor" id="H4270450"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Purulent pericarditis is a localized infection of the pericardial space producing fluid that is macroscopically or microscopically purulent. This distinction is important since purulent material in the pericardium is not synonymous with infectious pericarditis, and not all infections produce purulent effusions. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanisms by which patients develop purulent pericarditis include: direct spread from an intrathoracic focus of infection, hematogenous spread, extension from a myocardial focus, direct contamination from trauma or thoracic surgery, and extension from a subdiaphragmatic suppurative focus. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Staphylococcus aureus is the most common cause of purulent pericarditis. Other important pathogens include Streptococcus pneumoniae, Salmonella, Candida, and tuberculosis. Polymicrobial infections are uncommon. (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purulent pericarditis is typically an acute illness characterized by high fever, tachycardia, cough, and chest pain. Chest pain, however, is less common in purulent pericarditis than in acute pericarditis of other etiologies; when present it may be pleuritic or nonpleuritic. In the postoperative setting, most patients with purulent pericarditis have signs of mediastinitis or sternal wound infection. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of purulent pericarditis is established by obtaining pericardial fluid for culture and microscopy. Echocardiographically-guided pericardiocentesis is preferable. Pericardial fluid should be sent for protein, glucose and cell count, along with Gram stain, acid fast stain, fungal stain, and cultures. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment for purulent pericarditis consists of pericardial drainage and antimicrobial therapy. Pericardiocentesis is frequently the fastest way to drain the pericardial space, although thick fluid may either drain poorly or result in loculations in the pericardial space. Subxiphoid pericardiotomy usually allows more complete and permanent drainage than pericardiocentesis because a pericardial "window" is established during the procedure and because manual lysis of adhesions and loculations is easily accomplished. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous antimicrobial therapy should be started as soon as the diagnosis of purulent pericarditis is suspected. Initial empiric antibiotic treatment should include coverage for the likely or suspected pathogens. The selection of an empiric regimen depends on careful consideration of patient-specific factors that can give clues to an etiologic diagnosis. (See <a class="local">'Empiric regimen'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After a microbiologic diagnosis has been established by blood and/or pericardial fluid cultures, therapy should be directed at the specific pathogen isolated. The duration of therapy must be individualized. Intravenous therapy should be continued until fever and clinical signs of infection have resolved and until the white blood cell count is normal. In general this usually requires a total of two to four weeks of therapy. (See <a class="local">'Pathogen-directed therapy'</a> above and <a class="local">'Duration of therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rubin RH, Moellering RC Jr. Clinical, microbiologic and therapeutic aspects of purulent pericarditis. Am J Med 1975; 59:68.</a></li><li><a class="nounderline abstract_t">Boyle JO, Pearce ML, Guze LB. Purulent pericarditis. Review of the literature and report of eleven cases. Medicine (Baltimore) 1961; 40:119.</a></li><li><a class="nounderline abstract_t">Kenney RT, Li JS, Clyde WA Jr, et al. Mycoplasmal pericarditis: evidence of invasive disease. Clin Infect Dis 1993; 17 Suppl 1:S58.</a></li><li><a class="nounderline abstract_t">Sagristà-Sauleda J, Barrabés JA, Permanyer-Miralda G, Soler-Soler J. Purulent pericarditis: review of a 20-year experience in a general hospital. J Am Coll Cardiol 1993; 22:1661.</a></li><li><a class="nounderline abstract_t">Klacsmann PG, Bulkley BH, Hutchins GM. The changed spectrum of purulent pericarditis: an 86 year autopsy experience in 200 patients. Am J Med 1977; 63:666.</a></li><li><a class="nounderline abstract_t">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.</a></li><li><a class="nounderline abstract_t">Kauffman CA, Watanakunakorn C, Phair JP. Purulent pneumococcal pericarditis. A continuing problem in the antibiotic era. Am J Med 1973; 54:743.</a></li><li><a class="nounderline abstract_t">Miller WL, Osborn MJ, Sinak LJ, Westbrook BM. Pyopneumopericardium attributed to an esophagopericardial fistula: report of a survivor and review of the literature. Mayo Clin Proc 1991; 66:1041.</a></li><li><a class="nounderline abstract_t">KATZ A. ABSCESS OF THE MYOCARDIUM COMPLICATING INFARCTION: REPORT OF TWO CASES. Can Med Assoc J 1964; 91:1225.</a></li><li><a class="nounderline abstract_t">Schoenkerman AB, Lundstrom RJ. Coronary stent infections: a case series. Catheter Cardiovasc Interv 2009; 73:74.</a></li><li><a class="nounderline abstract_t">Ochsner A, DeBakey ME. Subphrenic abscess: Collective review and analysis of 3608 collected and personal cases. Int Abstr Surg 1938; 66:426.</a></li><li><a class="nounderline abstract_t">Ochsner A, DeBakey ME. Amebic hepatitis and hepatic abscess: analysis of 181 cases with review of the literature. Surgery 1943; 13:460.</a></li><li><a class="nounderline abstract_t">Myer, HW . Pneumopyopericardium. J Thorac Cardiovasc Surg 1948; 17:62.</a></li><li><a class="nounderline abstract_t">Parikh SV, Memon N, Echols M, et al. Purulent pericarditis: report of 2 cases and review of the literature. Medicine (Baltimore) 2009; 88:52.</a></li><li><a class="nounderline abstract_t">Brook I. Pericarditis caused by anaerobic bacteria. Int J Antimicrob Agents 2009; 33:297.</a></li><li><a class="nounderline abstract_t">Schrank JH Jr, Dooley DP. Purulent pericarditis caused by Candida species: case report and review. Clin Infect Dis 1995; 21:182.</a></li><li><a class="nounderline abstract_t">Kraus WE, Valenstein PN, Corey GR. Purulent pericarditis caused by Candida: report of three cases and identification of high-risk populations as an aid to early diagnosis. Rev Infect Dis 1988; 10:34.</a></li><li><a class="nounderline abstract_t">Cegielski P, Dukes CS. Pericardial effusion in AIDS. Circulation 1997; 96.</a></li><li><a class="nounderline abstract_t">Imazio M, Cecchi E, Demichelis B, et al. Myopericarditis versus viral or idiopathic acute pericarditis. Heart 2008; 94:498.</a></li><li><a class="nounderline abstract_t">Nwiloh JO, Egbe PA, Tagoe AT, Weaver LW. Staphylococcus aureus pericarditis masquerading as anterior mediastinal mass: mediastinal mass from pericarditis. Chest 2000; 118:1832.</a></li><li><a class="nounderline abstract_t">Pierce HI, Cooper EB. Meningococcal pericarditis. Clinical features andd therapy in five patients. Arch Intern Med 1972; 129:918.</a></li><li><a class="nounderline abstract_t">Morse JR, Oretsky MI, Hudson JA. Pericarditis as a complication of meningococcal meningitis. Ann Intern Med 1971; 74:212.</a></li><li><a class="nounderline abstract_t">Salem K, Mulji A, Lonn E. Echocardiographically guided pericardiocentesis - the gold standard for the management of pericardial effusion and cardiac tamponade. Can J Cardiol 1999; 15:1251.</a></li><li><a class="nounderline abstract_t">Nakagawa C, Kasahara K, Yonekawa S, et al. Purulent pericarditis due to Streptococcus pneumoniae diagnosed by pneumococcal urinary antigen assay and 16S rDNA sequence of the pericardial fluid. Intern Med 2010; 49:1653.</a></li><li><a class="nounderline abstract_t">Augustin P, Desmard M, Mordant P, et al. Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis. Crit Care 2011; 15:220.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown) 2010; 11:712.</a></li><li><a class="nounderline abstract_t">Van Trigt P, Douglas J, Smith PK, et al. A prospective trial of subxiphoid pericardiotomy in the diagnosis and treatment of large pericardial effusion. A follow-up report. Ann Surg 1993; 218:777.</a></li><li><a class="nounderline abstract_t">Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation 2011; 124:1270.</a></li></ol></div><div id="topicVersionRevision">Topic 2128 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1138554" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical, microbiologic and therapeutic aspects of purulent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Purulent pericarditis. Review of the literature and report of eleven cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399939" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Mycoplasmal pericarditis: evidence of invasive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227835" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Purulent pericarditis: review of a 20-year experience in a general hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/930941" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The changed spectrum of purulent pericarditis: an 86 year autopsy experience in 200 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4200204" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Purulent pneumococcal pericarditis. A continuing problem in the antibiotic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1921487" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pyopneumopericardium attributed to an esophagopericardial fistula: report of a survivor and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14226098" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ABSCESS OF THE MYOCARDIUM COMPLICATING INFARCTION: REPORT OF TWO CASES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19089964" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Coronary stent infections: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Subphrenic abscess: Collective review and analysis of 3608 collected and personal cases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Amebic hepatitis and hepatic abscess: analysis of 181 cases with review of the literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pneumopyopericardium</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19352300" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Purulent pericarditis: report of 2 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18789852" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pericarditis caused by anaerobic bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7578728" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Purulent pericarditis caused by Candida species: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3162595" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Purulent pericarditis caused by Candida: report of three cases and identification of high-risk populations as an aid to early diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pericardial effusion in AIDS</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575329" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Myopericarditis versus viral or idiopathic acute pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115484" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Staphylococcus aureus pericarditis masquerading as anterior mediastinal mass: mediastinal mass from pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4260723" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Meningococcal pericarditis. Clinical features andd therapy in five patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4993503" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pericarditis as a complication of meningococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10579740" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Echocardiographically guided pericardiocentesis - the gold standard for the management of pericardial effusion and cardiac tamponade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20686309" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Purulent pericarditis due to Streptococcus pneumoniae diagnosed by pneumococcal urinary antigen assay and 16S rDNA sequence of the pericardial fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21575282" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical review: intrapericardial fibrinolysis in management of purulent pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20736783" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8257228" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A prospective trial of subxiphoid pericardiotomy in the diagnosis and treatment of large pericardial effusion. A follow-up report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844077" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk of constrictive pericarditis after acute pericarditis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
